Global Information
회사소개 | 문의 | 비교리스트

뇌심부 자극 기기 시장 : 성장, 동향, 예측(2019-2024년)

Deep Brain Stimulation Devices Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2019년 05월 상품 코드 866757
페이지 정보 영문
US $ 4,250 ₩ 5,050,000 PDF (Single User License)
US $ 4,750 ₩ 5,644,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,130,000 PDF (Site License)
US $ 7,500 ₩ 8,913,000 PDF (Corporate License)

뇌심부 자극 기기 시장 : 성장, 동향, 예측(2019-2024년) Deep Brain Stimulation Devices Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 뇌심부 자극 기기(Deep Brain Stimulation Devices) 시장에 대해 조사했으며, 시장 개요, 성장 촉진요인 및 저해요인, 제품·용도·최종사용자·지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리했습니다.


제1장 서론

  • 조사 성과물
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 신경질환 위험과 높은 이환율을 가져오는 빠르게 증가하는 고령 인구
    • 최소침습 치료의 인기 상승에 따른 높아지는 수요
    • 기술적으로 진보한 뇌심부 자극 기기의 유용성
  • 시장 성장 저해요인
    • 뇌심부 자극 기기에 관련된 위험
    • 시장에 악영향을 미치는 정부 정책 실시
  • Porter’s Five Forces 분석
    • 신규 참여업체의 위협
    • 구매자/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 업계내 경쟁

제5장 시장 세분화

  • 제품 종류별
    • 싱글채널 뇌심부 자극 기기
    • 듀얼채널 뇌심부 자극 기기
  • 용도별
    • 파킨슨병
    • 본태성진전
    • 강박성 장애
    • 간질
    • 근육긴장이상
    • 기타
  • 최종사용자별
    • 병원
    • 외래수술센터
    • 신경과 클리닉
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Abbott Laboratories(St Jude Medical)
    • Beijing PINS Medical Co., Ltd.
    • Boston Scientific Corporation
    • Fisher Wallace
    • Functional Neuromodulation, Ltd
    • Medtronic Plc
    • NeuroPace Inc.
    • Renishaw plc

제7장 시장 기회 및 향후 동향

LSH 19.07.01

Market Overview

The major factors for the growth of the deep brain stimulation devices market include the rapidly aging population leading to risk and high prevalence of neurological disorders, growing demand for the devices due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

Deep Brain Stimulation (DBS) is a widely used treatment for the advanced Parkinson's disease (PD), essential tremor, and dystonia, and its clinical applications. However, in addition to the extension of the clinical applications of DBS over the last three decades, there has been tremendous growth in technology. Therefore, the advent of competition in the DBS industry has led to a surge of innovative technologies. Currently, there are multiple DBS systems that are approved by the European and US regulatory agencies. The US Food and Drug Administration (FDA) has recently approved Boston Scientific Corporation's Vercise Deep Brain Stimulation (DBS) System. This DBS system is used to treat the symptoms of Parkinson's disease (PD). Therefore, researchers are also improving their existing DBS systems, while developing the next generation of devices. The researchers are targeting DBS to different areas of the brain and studying the treatment in different populations of people living with Parkinson's. Although, some changes in the new systems have shown improvement in clinical outcomes. Nevertheless, these new developments in DBS technology are encouraging a large patient community and to the health care providers. Hence, all these new advancements in the technologies have to lead to an increase in the deep brain stimulation devices market.

Scope of the Report

As per the scope of this report, deep brain stimulator is a battery-operated medical device called neurostimulator, used in the neurosurgical procedure, which helps to treat a variety of disabling neurological symptoms. The market is segmented by product type, application, end user, and geography.

Key Market Trends

Parkinson's Disease is the Segment by Application is expected to Dominate the Market

The major factor driving the growth of the segment is the rising prevalence of Parkinson's diseases across the globe. According to Parkinson's news in 2018, approximately 1.2 million people in the United States are predicted to have Parkinson's disease by the year 2030. It is the second-most common neurodegenerative disorder in the United States. Similarly, as per the estimates of the NHS UK, Parkinson's disease is found affecting around 1 in 500 people, which means there are an estimated 127,000 people in the UK with the condition. In addition, there are thousands of patients who go undetected. DBS is the most commonly performed surgical treatment for Parkinson's. It is usually done in people who have had Parkinson's for at least four years and still get a benefit from medication but have motor complications. Furthermore, there is a rising technological advancement is going on in the field of DBS propelling overall growth of the market.

North America is Expected to Dominate the Market

According to the Parkinson's Foundation Prevalence Project, 930,000 people in the United States will be living with Parkinson disease by the year 2020. The combined direct and indirect costs of Parkinson's in the United States, including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at USD 25 billion per year in the United States alone. Hence, a growing burden of Parkinson's disease on the healthcare system coupled with uncertain economic conditions in the United States has forced the Original Equipment Manufacturers (OEMs) to develop cost-effective devices for the treatment of neurological movement disorders. The US Food and Drug Administration (FDA) has also approved another deep brain stimulation (DBS) device in 2015, for treatment of Parkinson's disease and essential tremor. The Brio System's approval has been good news for the Parkinson's patient community in the market, as it may stimulate more rapid development of DBS technology. Boston Scientific Corporation has received approval from the US Food and Drug Administration (FDA) in Dec 2017, for the Vercise Deep Brain Stimulation (DBS) System. Hence, all these recent product approvals and growing incidences of the Parkinson's disease have helped in driving the Deep Brain Stimulation Devices Market.

Competitive Landscape

The market studied is a consolidated market owing to the presence of the few major market players. Some of the market players are Abbott Laboratories (St Jude Medical), Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, Fisher Wallace, Functional Neuromodulation, Ltd, Medtronic Plc, NeuroPace Inc., and Renishaw plc

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapidly Aging Population Leading to Risk and High Prevalence of Neurological Disorders
    • 4.2.2 Growing Demand for the Devices due to Rising Popularity of Minimally Invasive Procedures
    • 4.2.3 Availability of Technologically Advanced Deep Brain Stimulation Devices
  • 4.3 Market Restraints
    • 4.3.1 Risks Associated with Deep Brain Stimulation Procedures
    • 4.3.2 Implementation of the Government Policies Negatively Affecting the Market
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Single Channel Deep Brain Stimulator
    • 5.1.2 Dual Channel Deep Brain Stimulator
  • 5.2 By Application
    • 5.2.1 Parkinson's Disease
    • 5.2.2 Essential Tremor
    • 5.2.3 Obsessive Compulsive Disorder
    • 5.2.4 Epilepsy
    • 5.2.5 Dystonia
    • 5.2.6 Other
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical centers
    • 5.3.3 Neurological Clinics
    • 5.3.4 Other
  • 5.4 Geography
    • 5.4.1 North America
      • US
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Argentina


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories (St Jude Medical)
    • 6.1.2 Beijing PINS Medical Co., Ltd.
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Fisher Wallace
    • 6.1.5 Functional Neuromodulation, Ltd
    • 6.1.6 Medtronic Plc
    • 6.1.7 NeuroPace Inc.
    • 6.1.8 Renishaw plc


Back to Top
전화 문의